{
    "id": 50747,
    "name": "lymphoplasmacytic lymphoma",
    "source": "DOID",
    "definition": "A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells. [url:http\\://en.wikipedia.org/wiki/Lymphoplasmacytic_lymphoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050747",
    "evidence": [
        {
            "id": 2623,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* demonstrated resistance to Imbruvica (Ibrutinib) in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2624,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S344fs demonstrated resistance to Imbruvica (Ibrutinib) in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9807,
                "profileName": "CXCR4 S344fs MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2625,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 T311fs demonstrated resistance to Imbruvica (Ibrutinib) in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9808,
                "profileName": "CXCR4 T311fs MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2626,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-treatment with Mozobil (plerixafor) overcame resistance to Imbruvica (Ibrutinib) in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2627,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-treatment with Mozobil (plerixafor) overcame resistance to Imbruvica (Ibrutinib) in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S344fs in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9807,
                "profileName": "CXCR4 S344fs MYD88 L265P"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2628,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-treatment with Mozobil (plerixafor) overcame resistance to Imbruvica (Ibrutinib) in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 T311fs in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9808,
                "profileName": "CXCR4 T311fs MYD88 L265P"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2629,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2630,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S344fs in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9807,
                "profileName": "CXCR4 S344fs MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2631,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 T311fs in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9808,
                "profileName": "CXCR4 T311fs MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2632,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing wild-type CXCR4 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9814,
                "profileName": "CXCR4 wild-type MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3967,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYD88 mutations are used in the diagnosis of lymphoplasmacytic lymphoma (Guidelines, PMID: 22944768, PMID: 26230596).",
            "molecularProfile": {
                "id": 1917,
                "profileName": "MYD88 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4315,
                    "pubMedId": 26230596,
                    "title": "Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26230596"
                },
                {
                    "id": 5214,
                    "pubMedId": 22944768,
                    "title": "IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr\u00f6m macroglobulinemia/lymphoplasmacytic lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22944768"
                },
                {
                    "id": 5215,
                    "pubMedId": null,
                    "title": "NCCN Guidelines Version 2.2016 Non-Hodgkin's Lymphomas",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7385,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of CXCR4 S338* in Waldenstrom macroglobulinemia cell lines conferred resistance to Imbruvica (ibrutinib) induced apoptosis in the presence of the Cxcr4 ligand Cxcl12 (Sdf-1a) in culture (PMID: 24912431).",
            "molecularProfile": {
                "id": 7764,
                "profileName": "CXCR4 S338*"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3107,
                    "pubMedId": 24912431,
                    "title": "The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24912431"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7386,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mozobil (plerixafor) to treament with Imbruvica (ibrutinib) overcame resistance to Imbruvica (ibrutinib), resulting in apoptosis in Waldenstrom macroglobulinemia cell lines expressing CXCR4 S338* cultured in the presence of the Cxcr4 ligand, Cxcl12 (Sdf-1a) (PMID: 24912431).",
            "molecularProfile": {
                "id": 7764,
                "profileName": "CXCR4 S338*"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3107,
                    "pubMedId": 24912431,
                    "title": "The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24912431"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9494,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VLX1570 induced apoptosis in Waldenstrom macroglobulinemia (WM) cell lines, including Velcade (bortezomib)-resistant cell lines, and primary WM cells in culture, and reduced tumor growth and increased survival in WM cell line xenograft models (PMID: 27813535).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5039,
                "therapyName": "VLX1570",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7224,
                    "pubMedId": 27813535,
                    "title": "Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27813535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16696,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Zydelig (idelalisib) treatment resulted in an overall response rate of 80% (8/10) in patients with lymphoplasmacytic lymphoma (PMID: 24450858; NCT01282424).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14717,
                    "pubMedId": 24450858,
                    "title": "PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24450858"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00577278",
            "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 767,
                    "therapyName": "Ibritumomab tiuxetan",
                    "synonyms": null
                },
                {
                    "id": 2238,
                    "therapyName": "Methotrexate + Sirolimus + Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2237,
                    "therapyName": "Fludarabine + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00602693",
            "title": "T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 2311,
                    "therapyName": "Allopurinol + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00671112",
            "title": "Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2234,
                    "therapyName": "Bortezomib + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01732913",
            "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01732926",
            "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                },
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01796171",
            "title": "A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7920,
                    "therapyName": "Lilotomab",
                    "synonyms": null
                },
                {
                    "id": 7393,
                    "therapyName": "Betalutin",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01955499",
            "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3580,
                    "therapyName": "Ibrutinib + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01994382",
            "title": "Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2531,
                    "therapyName": "Cerdulatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02000934",
            "title": "A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3146,
                    "therapyName": "TAK-659",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02049541",
            "title": "Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2502,
                    "therapyName": "Buparlisib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02092909",
            "title": "Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2866,
                    "therapyName": "IMO-8400",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02106091",
            "title": "Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7390,
                    "therapyName": "AFM11",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02180724",
            "title": "An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenstr\u00f6m Macroglobulinemia",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02367040",
            "title": "Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02369016",
            "title": "Phase III Copanlisib in Rituximab-refractory iNHL",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02384954",
            "title": "ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3936,
                    "therapyName": "ALT-803 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02604511",
            "title": "Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02626455",
            "title": "Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                },
                {
                    "id": 3388,
                    "therapyName": "Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                },
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02722668",
            "title": "UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2281,
                    "therapyName": "Cyclophosphamide + Fludarabine + Mycophenolate mofetil",
                    "synonyms": null
                },
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 1844,
                    "therapyName": "anti-thymocyte globulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02950220",
            "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4917,
                    "therapyName": "Ibrutinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03010358",
            "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8065,
                    "therapyName": "Entospletinib + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03015896",
            "title": "Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5239,
                    "therapyName": "Lenalidomide + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03037645",
            "title": "Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5281,
                    "therapyName": "SNS-062",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03053440",
            "title": "A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenstr\u00f6m's Macroglobulinemia (WM)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 2544,
                    "therapyName": "Zanubrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03133221",
            "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03225716",
            "title": "A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8081,
                    "therapyName": "Ibrutinib + Ulocuplumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03277729",
            "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9487,
                    "therapyName": "CD20 CAR T-cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03479268",
            "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7712,
                    "therapyName": "Ibrutinib + MLN4924",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03498612",
            "title": "Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03506373",
            "title": "Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7670,
                    "therapyName": "Ibrutinib + Ixazomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03537482",
            "title": "APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8825,
                    "therapyName": "APG-2575",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03601819",
            "title": "Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2006,
                    "therapyName": "Pacritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03679624",
            "title": "Daratumumab Plus Ibrutinib in Patients With Waldenstrom's Macroglobulinemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6744,
                    "therapyName": "Daratumumab + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03711578",
            "title": "Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2020,
                    "therapyName": "RP6530",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03884998",
            "title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6899,
                    "therapyName": "Copanlisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04043845",
            "title": "ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 8636,
                    "therapyName": "Ibrutinib + LY3214996",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04115059",
            "title": "Dasatinib In Waldenstrom Macroglobulinemia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                }
            ]
        }
    ]
}